GLP-1 receptor agonists, including semaglutide sold under the brand names Ozempic and Wegovy, have transformed obesity treatment. The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed that weekly subcutaneous semaglutide 2.4 mg produced an average weight loss of 15.3 percent of body weight over 68 weeks, a result that surpassed anything previously achievable with lifestyle intervention or earlier anti-obesity medications. Tirzepatide, which targets both GLP-1 and GIP receptors, has since shown average weight losses of up to 22 percent. These are genuinely impressive numbers, and for the right patient with significant obesity-related health risk, the cardiovascular and metabolic benefits are substantial and real. But there is a significant complication in the weight loss profile of these medications that is rarely communicated clearly to patients, rarely addressed proactively in prescribing, and potentially contributing to long-term harm for some users: a substantial proportion of the weight lost on GLP-1 agonists is skeletal muscle mass, not fat. Understanding this distinction and knowing what to do about it is essential for anyone on or considering these medications on the Isle of Man or anywhere in the UK.
How Much of GLP-1 Weight Loss Is Lean Mass?
Weight loss from any intervention includes both fat mass and lean mass. In well-designed lifestyle interventions combining caloric restriction with resistance training and adequate protein, the lean mass component of total weight loss is typically 20 to 25 percent, meaning 75 to 80 percent of the weight lost comes from fat. In GLP-1 agonist trials that included body composition measurement by DEXA or similar methods, the lean mass component appears to be higher. Sub-studies of the STEP trials and analyses from the SURMOUNT trials with tirzepatide have reported lean mass contributing 25 to 40 percent of total weight lost in some cohorts. For a person losing 15 kilograms on semaglutide, this translates to a loss of 4 to 6 kilograms of lean mass, approximately equivalent to the amount of muscle that would typically be lost over 5 to 8 years of normal ageing without exercise.
The clinical significance of this lean mass loss depends on the person's starting muscle mass and their age. For a 40-year-old with significant obesity who has substantial lean mass reserve, losing 5 kilograms of muscle alongside 10 kilograms of fat may represent a net health improvement, particularly given the dramatic metabolic benefits of the weight reduction. For a 65-year-old with already-borderline muscle mass who is on a GLP-1 agonist for weight management, the same lean mass loss may tip them from pre-sarcopenic to frankly sarcopenic, with consequences for falls risk, metabolic function, and functional independence that significantly offset the benefits of the fat reduction.
Why GLP-1 Drugs Cause Lean Mass Loss
The mechanisms behind GLP-1-associated lean mass loss are multi-factorial. The primary driver is the caloric deficit that these medications produce. GLP-1 agonists work largely through reducing appetite, slowing gastric emptying, and increasing satiety signals, producing spontaneous caloric restriction. In the STEP 1 trial, semaglutide-treated subjects reduced their caloric intake by approximately 24 percent below baseline. Any significant caloric restriction in the absence of specific countermeasures will produce lean mass loss alongside fat loss, because the body draws on both adipose tissue and muscle protein to meet energy requirements when intake is below expenditure. The larger the deficit, the more lean mass is at risk.
Additional factors include reduced protein intake secondary to decreased appetite, since many patients on GLP-1 agonists find high-protein foods less appealing or experience nausea with dense foods, and reduced physical activity if the medication's effects on appetite and energy also reduce motivation to exercise. Muscle is maintained not only through caloric adequacy but through the combination of sufficient protein and the mechanical stimulus of exercise. When both protein intake and physical activity decline alongside caloric restriction, the conditions for lean mass preservation are absent. Without deliberate strategies to counteract these effects, GLP-1-induced weight loss will include a disproportionate lean mass component.
Who Is Most at Risk from GLP-1-Associated Muscle Loss
The population at greatest risk from lean mass loss on GLP-1 agonists overlaps substantially with the population most commonly prescribed these medications: older adults with obesity-related type 2 diabetes or cardiovascular disease, many of whom have already-compromised muscle mass from years of physical inactivity, chronic disease-related catabolism, and the normal sarcopenic process of ageing. Research by Ida and colleagues published in Diabetology International in 2022 examined body composition changes in type 2 diabetes patients treated with GLP-1 agonists and found greater lean mass loss in older patients compared with younger ones, with the deficits most pronounced in those who did not perform resistance training during the treatment period.
Adults on the Isle of Man who are over 55, already at or near sarcopenic thresholds for muscle mass or strength, or who have limited physical activity levels face the highest risk from GLP-1-associated lean mass loss. For this group, the absence of a concurrent resistance training and protein intake strategy during GLP-1 treatment is not a missed opportunity for optimisation: it is a clinically significant oversight that could produce lasting harm. The responsibility for providing this guidance currently falls in the gap between the prescribing physician who manages the medication and the patient who has received no dietary or exercise prescription alongside it.
Practical Strategies for Preserving Muscle on GLP-1 Medications
The evidence for preserving lean mass during GLP-1-induced weight loss points clearly to two primary strategies: resistance training and adequate protein intake. Resistance training, ideally performed two to three times per week targeting all major muscle groups, maintains the mechanical stimulus for muscle protein synthesis during the weight loss period. The challenge is that reduced appetite from GLP-1 agonists may also reduce energy for exercise. Beginning an exercise programme before starting medication, or introducing it alongside the medication from the first week rather than waiting until weight loss is established, prevents the progressive deconditioning that compounds lean mass loss.
Protein intake requires explicit attention on GLP-1 medications. The target of 1.6 to 2.0 grams per kilogram of target body weight per day is already challenging for many adults in the absence of appetite suppression. When GLP-1 agonists reduce total food intake by 20 to 25 percent, maintaining protein at these levels while overall caloric intake is substantially reduced requires a deliberate shift towards protein-dense foods and potentially the use of supplemental protein. Liquid protein sources such as Greek yoghurt, cottage cheese, kefir, and protein supplements may be better tolerated than solid meats and fish if GI side effects are present. EMS offers an additional route to muscle stimulation for those whose exercise capacity is limited by fatigue or nausea during the early adaptation phase of GLP-1 treatment. At Zhen Wellness on the Isle of Man, clients on GLP-1 medications are assessed for muscle mass at baseline and throughout treatment, with programmes designed specifically to preserve lean tissue alongside the intended weight loss.
- STEP 1 trial shows semaglutide produces average 15.3% body weight loss; up to 40% of this may be lean mass in some cohorts
- For a 65-year-old on a GLP-1 agonist, lean mass loss may tip them from pre-sarcopenic to sarcopenic
- Primary causes: caloric deficit, reduced protein intake secondary to appetite suppression, reduced physical activity
- Older adults with already-compromised muscle mass are at greatest risk from GLP-1-associated lean mass loss
- Resistance training 2-3 times per week during treatment is the primary strategy for lean mass preservation
- Target 1.6-2.0 g protein per kg of target body weight daily; liquid protein sources may be better tolerated
- EMS can supplement resistance training for those with reduced exercise capacity during GLP-1 treatment
Sources
- Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
- Ida, S., et al. (2022). GLP-1 receptor agonist treatment and muscle mass change in people with type 2 diabetes. Diabetology International, 13(2), 532-541.
- Wadden, T.A., et al. (2021). Effect of subcutaneous semaglutide with and without phentermine on weight loss. JAMA, 325(14), 1403-1413.
- Jastreboff, A.M., et al. (2022). Tirzepatide versus semaglutide for obesity. New England Journal of Medicine, 387(3), 205-216.
- Bauer, J., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people. Journal of the American Medical Directors Association, 14(8), 542-559.